Bloomberg Law
Mergers & Acquisitions
LinkedIn

Pfizer to Buy Metsera for $4.9 Billion in Obesity Drug Bet (3)

Sept. 22, 2025, 1:36 PM UTC
Karen Leigh
Karen Leigh
Bloomberg News
Madison Muller
Madison Muller
Damian Garde
Damian Garde

Pfizer Inc. will pay $4.9 billion for the obesity startup Metsera Inc. in a bid to catch up to rival drugmakers after failing to compete with its own weight-loss medications.

The US drugmaker agreed to buy Metsera for $47.50 in cash per share, and further payments of up to $22.50 per share if three specific and regulatory milestones are met, it said Monday, with a total potential value of $7.3 billion. The deal represents a 43% premium to Metsera’s closing share price on Friday.

WATCH: Pfizer Inc. will pay $4.9 billion for the obesity startup Metsera Inc. in a bid to catch up to rival drugmakers after failing to compete with its own weight-loss medications Source: Bloomberg

Pfizer is in the process of rebuilding in the aftermath of the ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.